Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Globus Medical (GMED) Share Price

News coverage about Globus Medical (NYSE:GMED) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Globus Medical earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the medical device company an impact score of 46.2075745059208 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

GMED has been the topic of several recent analyst reports. Barclays PLC reaffirmed an “underweight” rating and issued a $28.00 price target (down previously from $30.00) on shares of Globus Medical in a research note on Thursday, August 3rd. Zacks Investment Research raised shares of Globus Medical from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a research report on Friday, May 5th. Gabelli reissued a “buy” rating on shares of Globus Medical in a research report on Friday, August 4th. Morgan Stanley reissued an “equal weight” rating on shares of Globus Medical in a research report on Tuesday, July 11th. Finally, Oppenheimer Holdings, Inc. set a $32.00 price objective on shares of Globus Medical and gave the stock a “hold” rating in a research report on Thursday, May 4th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company’s stock. Globus Medical currently has a consensus rating of “Hold” and a consensus price target of $30.43.

Globus Medical (NYSE GMED) traded down 1.22% during mid-day trading on Wednesday, reaching $29.23. 375,709 shares of the company were exchanged. Globus Medical has a 1-year low of $19.25 and a 1-year high of $34.03. The firm has a market capitalization of $2.81 billion, a P/E ratio of 26.33 and a beta of 0.60. The stock has a 50-day moving average of $31.56 and a 200 day moving average of $30.25.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Wednesday, August 2nd. The medical device company reported $0.32 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.02. Globus Medical had a return on equity of 13.99% and a net margin of 18.12%. The business had revenue of $152.39 million during the quarter, compared to the consensus estimate of $150.94 million. During the same period in the previous year, the business earned $0.29 EPS. The business’s quarterly revenue was up 10.8% on a year-over-year basis. Equities research analysts forecast that Globus Medical will post $1.27 earnings per share for the current year.

In other news, President Anthony L. Williams sold 16,153 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $31.94, for a total value of $515,926.82. Following the completion of the sale, the president now directly owns 16,153 shares in the company, valued at approximately $515,926.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 28.21% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/08/16/globus-medical-gmed-earns-daily-media-sentiment-score-of-0-15-updated.html.

Globus Medical Company Profile

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Insider Buying and Selling by Quarter for Globus Medical (NYSE:GMED)

What are top analysts saying about Globus Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Globus Medical Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit